相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella et al.
HEPATOLOGY (2023)
Liver fat as risk factor of hepatic and cardiometabolic diseases
Muenevver Demir et al.
OBESITY REVIEWS (2023)
Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Ulrich Kintscher et al.
BRITISH JOURNAL OF PHARMACOLOGY (2022)
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
Rajiv Agarwal et al.
EUROPEAN HEART JOURNAL (2022)
Association Between the Risk of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease
Pingping Zhao et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2022)
Liver fibrosis scores and prognosis in patients with cardiovascular diseases: A systematic review and meta-analysis
Zhiwei Yan et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2022)
Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems
Peter Kolkhof et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Mineralocorticoid receptors in the pathogenesis of insulin resistance and related disorders: from basic studies to clinical disease
Guanghong Jia et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2021)
Nonalcoholic Fatty Liver Disease-Associated Liver Fibrosis Is Linked with the Severity of Coronary Artery Disease Mediated by Systemic Inflammation
Ling-zi Chen et al.
DISEASE MARKERS (2021)
Performance of Fatty Liver Index in Identifying Non-Alcoholic Fatty Liver Disease in Population Studies. A Meta-Analysis
Marco Castellana et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Efficacy and safety of apararenone (MT-3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study
Takeshi Okanoue et al.
HEPATOLOGY RESEARCH (2021)
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
Bertram Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives
Michele Finotti et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
NAFLD as a driver of chronic kidney disease
Christopher D. Byrne et al.
JOURNAL OF HEPATOLOGY (2020)
Comparative study of spironolactone and eplerenone in management of ascites in patients of cirrhosis of liver
Rishabh Sehgal et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2020)
Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease
Hannes Hagstrom et al.
JOURNAL OF HEPATOLOGY (2020)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
Zobair M. Younossi et al.
JOURNAL OF HEPATOLOGY (2019)
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
George L. Bakris et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
Luis M. Ruilope et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes
Laura Sviklane et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2018)
Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity
Jana Grune et al.
HYPERTENSION (2018)
Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study
Hye Ryoun Jang et al.
SCIENTIFIC REPORTS (2018)
ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
Paul Y. Kwo et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
Urine albumin-to-creatinine ratio is associated with the severity of liver disease, renal function and survival in patients with decompensated cirrhosis
Evangelos Cholongitas et al.
HEPATOLOGY INTERNATIONAL (2017)
Comparison of Laboratory Tests, Ultrasound, or Magnetic Resonance Elastography to Detect Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: A Meta-Analysis
Guangqin Xiao et al.
HEPATOLOGY (2017)
Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease Role of Oxidative Stress
Lionel Lattenist et al.
HYPERTENSION (2017)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy A Randomized Clinical Trial
George L. Bakris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Comparison of Diagnostic Accuracy of Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis-4 Index for Detecting Liver Fibrosis in Adult Patients With Chronic Hepatitis B Virus Infection: A Systemic Review and Meta-analysis
Guangqin Xiao et al.
HEPATOLOGY (2015)
Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease
L. Fedchuk et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
Peter Kolkhof et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2014)
External Validation of the Fatty Liver Index for Identifying Nonalcoholic Fatty Liver Disease in a Population-based Study
Edith M. Koehler et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
Lars Baerfacker et al.
CHEMMEDCHEM (2012)
Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease
Stergios A. Polyzos et al.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2011)
Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease
Jeong-Hoon Lee et al.
DIGESTIVE AND LIVER DISEASE (2010)
Spironolactone Improves Glucose and Lipid Metabolism by Ameliorating Hepatic Steatosis and Inflammation and Suppressing Enhanced Gluconeogenesis Induced by High-Fat and High-Fructose Diet
Tsutomu Wada et al.
ENDOCRINOLOGY (2010)
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Amy G. Shah et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Increased Risk of CKD among Type 2 Diabetics with Nonalcoholic Fatty Liver Disease
Giovanni Targher et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients
Giovanni Targher et al.
DIABETES CARE (2007)
Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens
G. Targher
DIABETIC MEDICINE (2007)
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
Richard K. Sterling et al.
HEPATOLOGY (2006)
Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients
G Targher et al.
DIABETES (2005)
分享论文
